 |
Deposito minimo $50 Promozione esclusiva |
Il nostro punteggio |
0% commissione |
Are you looking to buy Myriad Genetics stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:MYGN! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Myriad Genetics stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Volume medio
1.00 million shs
TAPPA DEL MERCATO
$2.24 billion
Borsa valori
NASDAQ
Compri queste azioni!
|
NOME
|
TICKER
|
INDUSTRIA
|
SETTORE
|
VOLUME
|
COMPRI ORA QUESTE AZIONI
|
|---|---|---|---|---|---|
|
NASDAQ:MYGN
|
Diagnostic substances
|
Medico
|
9,055 shs
|
Below is a quick guide on how to buy NASDAQ:MYGN stocks safe, fast and around the world in less than five minutes.
Passo 1: Aprire un conto con eToro – eToro is the best broker to buy Myriad Genetics shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Passo 2: caricare il suo ID - Come da regolamento KYC eToro le chiederà di caricare una copia del suo passaporto o della sua patente di guida.
Passo 3: Deposito di fondi - Depositi del denaro nel suo conto eToro appena creato. Può scegliere tra bonifico bancario, e-wallet o carta di debito/credito o Paypal.
Passo 4: Buy Myriad Genetics – Search for “”NASDAQ:MYGN”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Myriad Genetics stocks with 0% commission!.
1 | | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Myriad Genetics in the last twelve months. There are currently 3 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “sell” Myriad Genetics stock.
Wall Street analysts have given Myriad Genetics a “Sell” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Myriad Genetics wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
2 |  | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
3 |  | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:MYGN stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Myriad Genetics stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Myriad Genetics stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Poiché eToro è una piattaforma regolamentata, dovrà completare il processo KYC, questa è una pratica standard e richiede solo un paio di minuti. Dovrà fornire un documento d'identità con foto (passaporto, patente) e una prova di indirizzo (bolletta, estratto conto bancario).
Una volta iscritto e verificato il suo conto, dovrà depositare dei fondi. eToro accetta carte di credito/debito, trasferimenti bancari e anche portafogli elettronici. Quindi qualunque sia la sua preferenza ci sarà qualcosa per lei.
Now that you’ve funded your eToro account, just type “NASDAQ:MYGN stocks" nella barra di ricerca nella parte superiore dello schermo e prema "trade".
All that’s left is to buy some NASDAQ:MYGN stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:MYGN is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Myriad Genetics stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Monday, November, 9th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.15. The business had revenue of $145.20 million for the quarter, compared to the consensus estimate of $134.59 million. Myriad Genetics had a negative net margin of 32.49% and a negative trailing twelve-month return on equity of 4.07%. The company’s revenue for the quarter was down 22.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.08 EPS.
View Myriad Genetics’ earnings history.
Myriad Genetics’ stock was trading at $14.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MYGN shares have increased by 109.3% and is now trading at $29.36.
5 equities research analysts have issued 12-month price targets for Myriad Genetics’ stock. Their forecasts range from $10.00 to $18.00. On average, they expect Myriad Genetics’ stock price to reach $13.25 in the next year. This suggests that the stock has a possible downside of 54.9%.
View analysts’ price targets for Myriad Genetics or view top-rated stocks among Wall Street analysts.
Myriad Genetics saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 7,770,000 shares, a drop of 14.6% from the December 31st total of 9,100,000 shares. Based on an average trading volume of 783,700 shares, the short-interest ratio is currently 9.9 days. Currently, 10.8% of the company’s stock are sold short.
View Myriad Genetics’ Short Interest.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:MYGN stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Oltre 95% dei fondi dei clienti sono tenuti offline, in depositi freddi, il che è fondamentale per qualsiasi broker che gestisce i suoi beni. Indipendentemente da quanto sia sicura una piattaforma, raccomandiamo di usare 2FA per aggiungere un ulteriore livello di sicurezza al suo conto.
eToro offre agli utenti una serie di caratteristiche per iniziare ad investire il più rapidamente possibile. Hanno una caratteristica relativamente unica chiamata copy trading, che le permette di guadagnare un reddito passivo facendo da specchio a trader esperti, questo le permette di iniziare a guadagnare rapidamente e le dà una migliore comprensione delle strategie usate dai professionisti. Inoltre, eToro permette agli utenti di investire in portafogli gestiti, un portafoglio gestito è una varietà di asset simili raggruppati insieme, che le permette di diversificare il suo conto, riducendo qualsiasi rischio potenziale. Per chi ha esperienza di trading precedente, può investire in mercati al di fuori delle azioni, dato che eToro permette agli utenti di commerciare ETF, materie prime, cripto e indici. Se già investe al di fuori dello spazio del mercato azionario questo può essere molto utile, perché le permette di gestire tutti i suoi investimenti in un solo posto.
Myriad Genetics’ management team includes the following people:
Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 50, Pay $741.84k)
Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 62, Pay $632.04k)
Ms. Nicole Lambert, Group Pres of Myriad Oncology, Myriad Women’s Health & Myriad International (Age 46, Pay $507.51k)
Mr. Paul J. Diaz, CEO, Pres & Director (Age 59)
Mr. Scott Gleason, Sr. VP of Investor Relations
Mr. Benjamin Jackson, Exec. VP, Gen. Counsel & Sec. (Age 42)
Dr. Clivetty Martinez, Chief Compliance Officer
Ms. Jayne Baird Hart, Exec. VP of HR (Age 61)
Mr. Paul Chip Parkinson, Exec. VP of Reimbursement Strategy
Mr. Mark S. Verratti, Pres of Myriad Neuroscience & Myriad Autoimmune (Age 53)
12 employees have rated Myriad Genetics CEO Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among Myriad Genetics’ employees.
I CFD sono strumenti complessi e comportano un alto rischio di perdere denaro rapidamente a causa della leva. Il 68% dei conti degli investitori al dettaglio perdono denaro quando scambiano CFD con questo fornitore. Deve considerare se capisce come funzionano i CFD e se può permettersi di correre l'alto rischio di perdere i suoi soldi.
Some companies that are related to Myriad Genetics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
View all of MYGN’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).
Myriad Genetics trades on the NASDAQ under the ticker symbol “MYGN.”
Myriad Genetics’ stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.62%), California Public Employees Retirement System (0.21%), Russell Investments Group Ltd. (0.20%), Comerica Bank (0.16%), State of Wisconsin Investment Board (0.13%) and Texas Permanent School Fund (0.08%). Company insiders that own Myriad Genetics stock include Alexander Ford, Bernard Tobin, Gary A King, John T Henderson, Nicole Lambert, Paul Parkinson, Ralph L Mcdade, Richard Bryan Riggsbee, S Louise Phanstiel and Walter Phd Gilbert.
View institutional ownership trends for Myriad Genetics.
1 | | Deposito minimo $50 Promozione esclusiva | Il nostro punteggio 10 ★★★★★ | 0% commissione |
MYGN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., State of Wisconsin Investment Board, State of Alaska Department of Revenue, Texas Permanent School Fund, SG Americas Securities LLC, Strs Ohio, California Public Employees Retirement System, and Pacer Advisors Inc.. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Nicole Lambert, and Paul Parkinson.
View insider buying and selling activity for Myriad Genetics or view top insider-selling stocks.
MYGN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Fisher Asset Management LLC, Zurcher Kantonalbank Zurich Cantonalbank , Joseph P. Lucia & Associates LLC, Nisa Investment Advisors LLC, Aperio Group LLC, and Comerica Bank. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, S Louise Phanstiel, and Walter Phd Gilbert.
View insider buying and selling activity for Myriad Genetics or or view top insider-buying stocks.
Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Recensione di Interactive Brokers, Recensione di eToro, Recensione di DEGiro, Recensione di AvaTrade, Recensione di IG Markets, Rassegna dei mercati IC, Recensione di CMC Markets, Recensione di Admiral Markets e molti altri. Legga una delle recensioni per scoprire tutto sul broker e inizi a comprare azioni ora.
One share of MYGN stock can currently be purchased for approximately $29.36.
Myriad Genetics has a market capitalization of $2.21 billion and generates $638.60 million in revenue each year. The company earns $-199,500,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.
Myriad Genetics employs 2,700 workers across the globe.
A Reportlab.org vogliamo assicurarci che lei abbia tutte le informazioni più rilevanti su acquisto di azioni. Le portiamo le migliori guide sul mercato azionario con recensioni personali, informazioni di base, recensioni di piattaforme, how to's e altro. Vuole ottenere altre informazioni? Allora dia un'occhiata al Azioni OTC, Azioni del NASDAQ, Azioni del NYSE, Azioni LON, Scorte FRA, Azioni ETR, Scorte dell'EPA, Azioni del TSX o Azioni Amex. Cercando informazioni più dettagliate come 5g stock, azioni biotecnologiche, azioni d'oro e altre informazioni dal nostro reportlab.
How can you buy Myriad Genetics stock on the internet?
You can easily buy Myriad Genetics stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Un'altra opzione è usare un broker regolamentato come Mercati IC o Brokers interattivi. You can an account with these brokers and start buying or trading NASDAQ:MYGN stocks in a safe and complete environment to trade in.
Where to buy Myriad Genetics stock?
You will first want to find a licensed broker that supports NASDAQ:MYGN stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:MYGN stocks in a safe and complete environment.
Is NASDAQ:MYGN stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:MYGN stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Myriad Genetics stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:MYGN is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Myriad Genetics stock.
How do you trade Myriad Genetics stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Myriad Genetics stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:MYGN stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Myriad Genetics stock?
To sell your NASDAQ:MYGN stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Myriad Genetics stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:MYGN stock.
Stephen conosce molto bene i prodotti finanziari e in particolare ha una grande passione per i mercati azionari e i suoi partecipanti. Speriamo che le informazioni fornite le siano utili. C'è qualcosa di poco chiaro? Lasci le sue domande o commenti in fondo alla pagina.
| Il nostro punteggio ★★★★★ | |
| Il nostro punteggio ★★★★★ | |
| Il nostro punteggio ★★★★★ |
Notiziario
Notizie recenti
| |
Il nostro punteggio |
0% commissione |
Dati in tempo reale su azioni e criptovalute
Notifiche, Consigli e Notizie
Le migliori guide su azioni e criptovalute
Recensioni su broker e scambi online
Reportlab Finanza è un sito web puramente informativo e non implica in nessun caso consigli di investimento. Tutti gli investimenti comportano rischi e lei può perdere tutti i suoi investimenti. Non investa denaro che non può permettersi di perdere.
Reportlab Finanza
38 Holburn Lane
Heckfield Green
IP21 0UB
Regno Unito
Copyright © 2022 Reportlab.Finance | Tutti i diritti riservati.
